Skin Cancers

Key Efficacy End Points Upheld at 3 Years for Cemiplimab in CSCC

May 31, 2020

“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”

Combination Regimens Inspire Hope for the Treatment of Melanoma

May 04, 2020

In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.

ILLUMINATE-204 Update: Promising Results Reported With Tilsotolimod Plus Ipilimumab in Advanced Melanoma

April 21, 2020

"The clinical benefit suggested for these anti-PD-1 refractory melanoma patients with limited treatment options includes stabilization of disease and even responses, which is creating hope that this combination might be of benefit to patients in the PD-1 refractory setting."